R&D Systems Inc. Tocris Bioscience Boston Biochem

RS 102895 hydrochloride

Cat. No. 2089

RS 102895 hydrochloride C21H21F3N2O2.HCl [1173022-16-6]

Price and Availability

For RS 102895 hydrochloride pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 1'-[2-[4-(Trifluoromethyl)phenyl]ethyl]-spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one hydrochloride

Biological Activity

CCR2-selective chemokine receptor antagonist (IC50 values are 0.36 and 17.8 μM for inhibition of human recombinant CCR2b and CCR1 receptors respectively). Blocks MCP-1-stimulated calcium influx and chemotaxis with IC50 values of 32 nM and 1.7 μM respectively. Also inhibits α1A, α1D and 5-HT1A receptors.

Technical Data

M.Wt:
426.86
Formula:
C21H21F3N2O2.HCl
Solubility:
Soluble to 75 mM in DMSO
Purity:
>99 %
Storage:
Desiccate at RT
CAS No:
1173022-16-6

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

References

Clark et al (1983) Synthesis and antihypertensive activity of 4'-substituted spiro[4H-3,1-benzoxazine-4,4'piperidin]-2(1H)-ones. J.Med.Chem. 26 657. PMID: 6842505.

Mirzadegan et al (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J.Biol.Chem. 275 25562. PMID: 10770925.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Keywords: RS 102895 hydrochloride, supplier, CCR2b, chemokine, receptor, antagonists, Chemokine, Receptors, RS102895, hydrochloride

Quick Order

Find multiple products by catalog number

divider line

Immunology Guide

Immunology Research Guide

Highlights over 150 products for immunology research. Request a copy or view PDF today.

divider line

New Therapies and Challenges in Asthma

Written by Peter J. Barnes

Asthma Poster

'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.

divider line

7-TM Receptor Signaling

Written by T. Kenakin et al

7-TM Poster

'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

New Product Guide

NPG

Highlights over 130 new products added in the second half of 2013. Request a copy or view PDF today.

divider line

New Products in this Area

AS 2034178

Selective FFA1 (GPR40) agonist

(±)-NBI 74330

Potent and selective CXCR3 antagonist

Purmorphamine

Smo receptor agonist

CTCE 9908

CXCR4 antagonist; antitumor

VUF 11207 fumarate

Potent CXCR7 agonist

TC-G 1006

Potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist

DMNPE-caged ATP diammonium salt

Caged ATP

MK 1903

Potent and selective GPR109A (HCA2) agonist

M 25

Potent Smoothened (Smo) receptor antagonist

Ki 16425

LPA1 and LPA3 receptor antagonist

CYM 50358 hydrochloride

Potent and selective S1P4 antagonist

(±)-AMG 487

CXCR3 antagonist; inhibits cell migration and metastasis

GW 627368

Selective EP4 receptor competitive antagonist

Sign-up for new product e-alerts
divider line

Tocris Events

Meet your representative

R&D Symposium 2014

Molecular Mechanisms in Signal Transduction

July 15, 2014

Cambridge, UK